Wednesday, July 8, 2026

pharma · SBRT · Covid19 · GRTX

Kailera Therapeutics

Kailera Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker GRTX. Primary therapeutic focus areas include SBRT, Covid19, Head and Neck Cancer, Oral Mucositis, Esophagitis.

Waltham, Massachusetts, United States HQ
2024 Founded
153 Employees
Public company Type
GRTX · NYSE Ticker
Company details
Status
Public
HQ
Waltham, Massachusetts, United States
Founded
2024
Employees
153
Programs
17
Drugs
7
Patents
23

Quick answer

Kailera Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker GRTX. Primary therapeutic focus areas include SBRT, Covid19, Head and Neck Cancer, Oral Mucositis, Esophagitis. NovaPharmaNews links 17 clinical program(s), 0 drug profile(s), and 23 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (9), phase 2 (7), phase 3 (1).

Company snapshot

Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.

  • 17 active pipeline program(s) linked via ClinicalTrials.gov.
  • 23 US patent(s) indexed to this assignee profile.
  • 17 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Kailera Therapeutics. Not investment advice.

Recent coverage

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for Kailera Therapeutics.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 17 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Recent activity

Latest pipeline, patent, and corporate events for Kailera Therapeutics.

  1. Clinical update

    Low Dose GC4419: 30mg/day — Phase 2

  2. Clinical update

    Dextromethorphan HBr — Phase 1

  3. Clinical update

    GC4711 Oral Capsule G-101 — Phase 1

  4. Clinical update

    GC4702 dry powder — Phase 1

  5. Clinical update

    GC4419 90mg — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Kailera Therapeutics?

    Kailera Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker GRTX. Primary therapeutic focus areas include SBRT, Covid19, Head and Neck Cancer, Oral Mucositis, Esophagitis. NovaPharmaNews links 17 clinical program(s), 0 drug profile(

  • Is Kailera Therapeutics publicly traded?

    Yes. Kailera Therapeutics is listed with ticker GRTX on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does Kailera Therapeutics develop or market?

    We link 7 drug profile(s) where Kailera Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/galera-therapeutics#company-drugs.

  • What are the latest developments for Kailera Therapeutics?

    In the last 12 months our linked public records show 17 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Kailera Therapeutics focus on?

    Kailera Therapeutics focuses on SBRT, Covid19, Head and Neck Cancer based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
22
Oncology
4
Neurology
1